A Phase 1 Dose Escalation and Expansion Study of EO-3021, an Anti-claudin 18.2 (CLDN18.2) Antibody Drug Conjugate, in Patients with Solid Tumors Likely to Express CLDN18.2
NCT #
NCT05980416
Condition(s)
Esophageal Cancer, Gastric/GEJ Cancer, Lung Cancer (NSCLC), Ovarian/ Peritoneal/ Fallopian Tube Cancer, Pancreatic Cancer, Solid Tumor
Molecular Target(s)
CLDN18.2
Drug Classification(s)
Antibody Drug Conjugate
Agents(s)
EO-3021
Phase(s)
I
Mechanism of Action
EO-3021 is an anti-CLDN18.2 antibody drug conjugate.
Purpose
- How much of the study agent can be given with an acceptable level of side effects
- The effects of the study agent (good and bad)
- How much of the study agent is absorbed into the blood and how fast it is removed
- How the study agent is acting on your body
- Whether proteins in the blood and tissue samples can predict if someone has a better or worse response to the study agent
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target
Conditions
Publications
24-08
RMC-6291 is a tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein RMC-6236 is a RASMULTI(ON) inhibitor
Molecular Targeted Therapy, Small Molecule
KRAS
Solid Tumor
Yes
24-05
BG-68501 is a CDK2 Inhibitor
CDK2 Inhibitor, Molecular Targeted Therapy
CDK2
Solid Tumor
No
24-01
NM32-2668 is an anti-ROR1/Anti-CD3/Anti-HAS Tri-specific Antibody
Molecular Targeted Therapy, Trispecific Antibodies
ROR1
Breast Cancer, Endometrial Cancer, Gastric/GEJ Cancer, Leiomyosarcoma, liposarcoma, Lung Cancer (NSCLC), Mesothelioma, Ovarian/ Peritoneal/ Fallopian Tube Cancer, Renal Cell Cancer, Skin Cancer/ Melanoma
Yes
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.